| 104.53 0.03 (0.03%) | 04-27 13:26 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 127.93 | 1-year : | 149.42 |
| Resists | First : | 109.52 | Second : | 127.93 |
| Pivot price | 105.44 |
|||
| Supports | First : | 99.87 | Second : | 93.91 |
| MAs | MA(5) : | 106.79  |
MA(20) : | 104.78 |
| MA(100) : | 103.08 |
MA(250) : | 90.84 |
|
| MACD | MACD : | 1.5 |
Signal : | 1.5 |
| %K %D | K(14,3) : | 63.7 |
D(3) : | 75.3 |
| RSI | RSI(14): 53.4 |
|||
| 52-week | High : | 113.01 | Low : | 63.55 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ NUVL ] has closed below upper band by 49.9%. Bollinger Bands are 20.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 108.83 - 109.51 | 109.51 - 109.99 |
| Low: | 102.9 - 103.74 | 103.74 - 104.33 |
| Close: | 103.41 - 104.63 | 104.63 - 105.48 |
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Sun, 26 Apr 2026
Does Nuvalent (NUVL) have the potential to rally 37.26% as Wall Street analysts expect? - MSN
Wed, 08 Apr 2026
Nuvalent (NUVL) CEO trades 30K shares after option exercises - Stock Titan
Thu, 02 Apr 2026
[Form 4] Nuvalent, Inc. Insider Trading Activity - Stock Titan
Thu, 05 Feb 2026
Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 73 (M) |
| Shares Float | 49 (M) |
| Held by Insiders | 2.7 (%) |
| Held by Institutions | 111.4 (%) |
| Shares Short | 4,980 (K) |
| Shares Short P.Month | 5,540 (K) |
| EPS | -5.85 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 15.94 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -20.3 % |
| Return on Equity (ttm) | -36.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -275 (M) |
| Levered Free Cash Flow | -142 (M) |
| PE Ratio | -18.03 |
| PEG Ratio | 0 |
| Price to Book value | 6.61 |
| Price to Sales | 0 |
| Price to Cash Flow | -28.05 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|